

# What we need ...

# ... to make life with atopic eczema better for all



## Improving the lives of those with atopic eczema

# Our call to policy makers:

1

Recognition that Atopic Eczema (Atopic Dermatitis) is a growing health crisis Atopic eczema is the most common inflammatory skin disease, affecting up to one in five (20%) of children and adolescents worldwide and one in 10 (10%) of adults.¹ Recent research shows that its incidence is growing.²,³ Yet, it remains a low priority in many healthcare systems and is chronically under-researched.

#### We call on all governments and healthcare systems to:

- Prioritise healthcare and epidemiological research to map incidence of atopic eczema
- Develop dermatology strategies, frameworks and plans to meet this growing need
- Invest in scientific and clinical research to further our understanding of the disease

2

Ensure timely access to dermatology specialists and mental health support Despite its high incidence, children and adults with atopic eczema face agonising waits to see a dermatologist, and many do not have access to a dermatologist at all.<sup>4,5,6</sup> This puts tremendous pressure on primary care physicians, with an estimated 24% of primary care consultations focused on skin diseases.<sup>7</sup> Despite this pressure, dermatological training for primary care health practitioners is still not prioritised.<sup>7</sup> Furthermore, atopic eczema is associated with several mental health co-morbidities, particularly attention-deficit hyperactivity disorder, anxiety, and depression.<sup>8</sup> Access to mental health support is often lacking, leaving children and adults without adequate help.

#### We call on all governments and healthcare systems to:

- Invest in expanding the number of specialist dermatologists
- Strengthen and expand dermatological training programmes for primary care physicians and related healthcare experts
- Expand access to mental health support for those with atopic eczema

3

#### Ensure reimbursed or affordable access to appropriate treatments

A range of treatment options exist for children and adults with atopic eczema, including biologic therapies. Affordable access to these therapies is often missing or severely restricted, meaning that many cannot receive adequate care. Evidence also shows that racial and ethnic disparities exist even when these treatments are available. This is putting a financial burden on families, with one study estimating €927 per patient in additional personal costs per year, to self-fund essential medicines such as emollients and creams. descriptions of the control of the control

#### We call on all governments and healthcare systems to:

- Support wider reimbursed and/or affordable access to essential medicines
- Ensure unhindered access to newer medicines that have demonstrated effectiveness and value



### Improving the lives of those with atopic eczema

## References

- 1: The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017: M.R. Laughter et al, British Journal of Dermatology V 184, 2, P 304-309
- 2: Mohn CH et al, Incidence Trends of Atopic Dermatitis in Infancy and Early Childhood in a Nationwide Prescription Registry Study in Norway. JAMA Netw Open. 2018;1(7):e184145. doi:10.1001/jamanetworkopen.2018.4145
- 3: Hajar T at al, The Rise in Atopic Dermatitis in Young Children: What Is the Explanation? JAMA Netw Open. 2018;1(7):e184205. doi:10.1001/jamanetworkopen.2018.4205
- 4: Creadore A et al. Insurance Acceptance, Appointment Wait Time, and Dermatologist Access Across Practice Types in the US. JAMA Dermatol. 2021;157(2):181–188. doi:10.1001/jamadermatol.2020.5173
- 5: Barry K K, et al, Access to paediatric dermatology, Current Opinion in Paediatrics, Volume 34, Number 4, August 2022, pp. 359-366(8)
- 6: Toy J B S, Barriers to healthcare access in pediatric dermatology: A systematic review, Paediatric Dermatology, 2021, Vol 38, 52, pp. 13-19
- 7: Ball N et al, Current Issues in Primary Care Dermatology, Dermatological Nursing, Dec 2019, Vol 18, Issue 4, pp. 27-30
- 8: Paller A, et al, Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders, American Journal of Clinical Dermatology, 2018, Vol 19, pp. 821-838
- 9: Bell M A, et al, Racial and Ethnic Disparities in Access to Emerging and Frontline Therapies in Common Dermatological Conditions: A Cross-Sectional Study, Journal of the National Medicine Association, 2020 Vol 112, Issue 6, pp. 650-653
- 10: Zink A et al, Out-of-pocket Costs for Individuals with Atopic Eczema: A Cross-sectional Study in Nine European Countries, ActaDV, 2019, Vol 99, Issue 3

